

2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)

Developed with the special contribution of the Heart Failure Association (HFA) of the ESC

ESC Chairperson

Piotr Ponikowski

Department of Heart Diseases,
Wroclaw Medical University,
Centre for Heart Diseases, Military Hospital, ul.
Weigla 5, 50-981 Wroclaw, Poland

Tel: +48 261 660 279

Tel/Fax: +48 261 660 237

E-mail: E-mail: piotrponikowski@4wsk.pl

Co- Chairperson

Adriaan Voors

Cardiology, University of Groningen,
University Medical Center Groningen, Hanzeplein 1,
PO Box 30.001,
9700 RB Groningen, The Netherlands

Tel: +31 50 3612355

Fax: +31 50 3614391

E-mail: a.a.voors@umcg.nl

Task Force Members: Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK), Volkmar Falk (Germany), José Ramón González-Juanatey (Spain), Veli-Pekka Harjola (Finland), Ewa A. Jankowska (Poland), Mariell Jessup (USA), Cecilia Linde (Sweden), Petros Nihoyannopoulos (UK), John T. Parissis (Greece), Burkert Pieske (Germany), Jillian P. Riley (UK), Giuseppe M. C. Rosano (UK/Italy), Luis M. Ruilope (Spain), Frank Ruschitzka (Switzerland), Frans H. Rutten (The Netherlands), Peter van der Meer (The Netherlands).

Document Reviewers: Gerasimos Filippatos (CPG Review Coordinator) (Greece), John J. V. McMurray (CPG Review Coordinator) (UK), Victor Aboyans (France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Nawwar Al-Attar (UK), John James Atherton (Australia), Johann Bauersachs (Germany), A. John Camm (UK), Scipione Carerj (Italy), Claudio Ceconi (Italy), Antonio Coca (Spain), Perry Elliott (UK), Çetin Erol (Turkey), Justin Ezekowitz (Canada), Covadonga Fernández-Golfín (Spain), Donna Fitzsimons (UK), Marco Guazzi (Italy),

ESC Levels of evidence

Level of Evidence A	Data derived from multiple randomized clinical trials or meta-analyses.
Level of Evidence B	Data derived from a single randomized clinical trial or large non-randomized studies.
Level of Evidence C	Consensus of opinion of the experts and/or small studies, retrospective studies, registries.

ESC Classes of recommendations

Classes of recommendations	Definition	Suggested wording to use
Class I	Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.	Is recommended/ is indicated.
Class II	Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.	
Class IIa	<i>Weight of evidence/opinion is in favour of usefulness/efficacy.</i>	Should be considered.
Class IIb	<i>Usefulness/efficacy is less well established by evidence/opinion.</i>	May be considered.
Class III	Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.	Is not recommended.

Definition of heart failure

**With preserved (HFpEF), mid-range (HFmrEF)
and reduced ejection fraction (HFrEF)**

Type of HF		HFrEF	HFmrEF	PFpEF
CRITERIA	1	Symptoms ± Signs	Symptoms ± Signs	Symptoms ± Signs
	2	LVEF <40%	LVEF 40-49%	LVEF ≥ 50%
	3	-	1.Elevated levels of natriuretic peptides. 2.At least one additional criterion: a.relevant structural heart disease (LVF and/or LAE); b.diastolic dysfunction (for details see Section 4.3.2.).	1.Elevated levels of natriuretic peptides. 2.At least one additional criterion: a.relevant structural heart disease (LVF and/or LAE); b.diastolic dysfunction (for details see Section 4.3.2.).

Aetiologies of heart failure (1)

DISEASED MYOCARDIUM		
Ischaemic heart disease	Myocardial scar	
	Myocardial stunning/hibernation	
	Epicardial coronary artery disease	
	Abnormal coronary microcirculation	
	Endothelial dysfunction	
Toxic damage	Recreational substance abuse	Alcohol, cocaine, amphetamine, anabolic steroids.
	Heavy metals	Copper, iron, lead, cobalt.
	Medications	Cytostatic drugs (e.g. anthracyclines), immunomodulating drugs (e.g. interferons monoclonal antibodies such as trastuzumab, cetuximab), antidepressant drugs, antiarrhythmics, non-steroidal anti-inflammatory drugs, anaesthetics.
	Radiation	

Aetiologies of heart failure (2)


DISEASED MYOCARDIUM (cont'd)		
Immune-mediated and inflammatory damage	Related to infection	Bacteria, spirochaetes, fungi, protozoa, parasites (Chagas disease), rickettsiae, viruses (HIV/AIDS).
	Not related to infection	Lymphocytic/giant cell myocarditis, autoimmune diseases (e.g. Graves' disease, rheumatoid arthritis, connective tissue disorders, mainly systemic lupus erythematosus), hyper-sensitivity and eosinophilic myocarditis (Churg–Strauss).
Infiltration	Related to malignancy	Direct infiltrations and metastases.
	Not related to malignancy	Amyloidosis, sarcoidosis, haemochromatosis (iron), glycogen storage diseases (e.g. Pompe disease), lysosomal storage diseases (e.g. Fabry disease).
Metabolic derangements	Hormonal	Thyroid diseases, parathyroid diseases, acromegaly, GH deficiency, hypercortisolaemia, Conn's disease, Addison disease, diabetes, metabolic syndrome, pheochromocytoma, pathologies related to pregnancy and peripartum.
	Nutritional	Deficiencies in thiamine, L-carnitine, selenium, iron, phosphates, calcium, complex malnutrition (e.g. malignancy, AIDS, anorexia nervosa), obesity.
Genetic abnormalities	Diverse forms	HCM, DCM, LV non-compaction, ARVC, restrictive cardiomyopathy (for details see respective expert documents), muscular dystrophies and laminopathies.

Aetiologies of heart failure (3)

ABNORMAL LOADING CONDITIONS		
Hypertension		
Valve and myocardium structural defects	Acquired	Mitral, aortic, tricuspid and pulmonary valve diseases.
	Congenital	Atrial and ventricular septum defects and others (for details see a respective expert document).
Pericardial and endomyocardial pathologies	Pericardial	Constrictive pericarditis. Pericardial effusion.
	Endomyocardial	HES, EMF, endocardial fibroelastosis.
High output states		Severe anaemia, sepsis, thyrotoxicosis, Paget's disease, arteriovenous fistula, pregnancy.
Volume overload		Renal failure, iatrogenic fluid overload.
ARRHYTHMIAS		
Tachyarrhythmias		Atrial, ventricular arrhythmias.
Bradyarrhythmias		Sinus node dysfunctions, conduction disorders.

Symptoms and signs typical of heart failure

Symptoms	Signs
Typical <ul style="list-style-type: none"> • Breathlessness • Orthopnoea • Paroxysmal nocturnal dyspnoea • Reduced exercise tolerance • Fatigue, tiredness, increased time to recover after exercise • Ankle swelling 	More specific <ul style="list-style-type: none"> • Elevated jugular venous pressure • Hepatojugular reflux • Third heart sound (gallop rhythm) • Laterally displaced apical impulse
Less typical <ul style="list-style-type: none"> • Nocturnal cough • Wheezing • Bloating feeling • Loss of appetite • Confusion (especially in the elderly) • Depression • Palpitations • Dizziness • Syncope • Bendopnea 	Less specific <ul style="list-style-type: none"> • Weight gain (>2 kg/week) • Weight loss (in advanced HF) • Tissue wasting (cachexia) • Cardiac murmur • Peripheral oedema (ankle, sacral, scrotal) • Pulmonary crepitations • Reduced air entry and dullness to percussion at lung bases (pleural effusion) • Tachycardia • Irregular pulse • Tachypnoea • Cheyne Stokes respiration • Hepatomegaly • Ascites • Cold extremities • Oliguria • Narrow pulse pressure



Cardiac imaging in patients with suspected or established heart failure (1)

Recommendations	Class	Level
TTE is recommended for the assessment of myocardial structure and function in subjects with suspected HF in order to establish a diagnosis of either HFrEF, HFmrEF or HFpEF.	I	C
TTE is recommended to assess LVEF in order to identify patients with HF who would be suitable for evidence-based pharmacological and device (ICD, CRT) treatment recommended for HFrEF.	I	C
TTE is recommended for the assessment of valve disease, right ventricular function and pulmonary arterial pressure in patients with an already established diagnosis of either HFrEF, HFmrEF or HFpEF in order to identify those suitable for correction of valve disease.	I	C
TTE is recommended for the assessment of myocardial structure and function in subjects to be exposed to treatment which potentially can damage myocardium (e.g. chemotherapy).	I	C
Other techniques (including systolic tissue Doppler velocities and deformation indices, i.e. strain and strain rate), should be considered in a TTE protocol in subjects at risk of developing HF in order to identify myocardial dysfunction at the prediagnosed stage.	IIa	C
CMR is recommended for the assessment of myocardial structure and function (including right heart) in subjects with poor acoustic window and patients with complex congenital heart diseases (taking account of cautions/contra-indications to CMR).	I	C
CMR with LGE should be considered in patients with dilated cardiomyopathy in order to distinguish between ischaemic and nonischaemic myocardial damage in case of equivocal clinical and other imaging data (taking account of cautions/contra-indications to CMR).	IIa	C
CMR is recommended for the characterization of myocardial tissue in case of suspected myocarditis, amyloidosis, sarcoidosis, Chagas disease, Fabry disease non-compaction cardiomyopathy, and haemochromatosis (taking account of cautions/ contra-indications to CMR).	I	C

Cardiac imaging in patients with suspected or established heart failure (2)

Recommendations	Class	Level
Non-invasive stress imaging (CMR, stress echocardiography, SPECT, PET) may be considered for the assessment of myocardial ischaemia and viability in patients with HF and CAD (considered suitable for coronary revascularization) before the decision on revascularization.	IIb	B
Invasive coronary angiography is recommended in patients with HF and angina pectoris recalcitrant to pharmacological therapy or symptomatic ventricular arrhythmias or aborted cardiac arrest (who are considered suitable for potential coronary revascularization) in order to establish the diagnosis of CAD and its severity.	I	C
Invasive coronary angiography should be considered in patients with HF and intermediate to high pre-test probability of CAD and the presence of ischaemia in non-invasive stress tests (who are considered suitable for potential coronary revascularization) in order to establish the diagnosis of CAD and its severity.	IIa	C
Cardiac CT may be considered in patients with HF and low to intermediate pre-test probability of CAD or those with equivocal non-invasive stress tests in order to rule out coronary artery stenosis.	IIb	C
Reassessment of myocardial structure and function is recommended using non-invasive imaging: <ul style="list-style-type: none"> - in patients presenting with worsening HF symptoms (including episodes of AHF) or experiencing any other important cardiovascular event; - in patients with HF who have received evidence-based pharmacotherapy in maximal tolerated doses, before the decision on device implantation (ICD, CRT); - in patients exposed to therapies which may damage the myocardium (e.g. chemotherapy) (serial assessments). 	I	C

Diagnostic tests in patients with heart failure (1)

Recommendations	Class	Level
<p>The following diagnostic tests are recommended/should be considered for initial assessment of a patient with newly diagnosed HF in order to evaluate the patient's suitability for particular therapies, to detect reversible/treatable causes of HF and co-morbidities interfering with HF:</p> <ul style="list-style-type: none"> - haemoglobin and WBC, - sodium, potassium, urea, creatinine (with estimated GFR), - liver function tests (bilirubin, AST, ALT, GGTP), - glucose, HbA1c, - lipide profile, - TSH, - ferritin, TSAT = TIBC, - natriuretic peptides. 	I	C
	IIa	C
<p>Additional diagnostic tests aiming to identify other HF aetiologies and co-morbidities should be considered in individual patients with HF when there is a clinical suspicion of a particular pathology (see Full Text Table 3.4 on HF aetiologies).</p>	IIa	C

Diagnostic tests in patients with heart failure (2)

Recommendations	Class	Level
A 12-lead ECG is recommended in all patients with HF in order to determine heart rhythm, heart rate, QRS morphology, and QRS duration, and to detect other relevant abnormalities. This information is needed to plan and monitor treatment.	I	C
Exercise testing in patients with HF:		
– is recommended as a part of the evaluation for heart transplantation and/or mechanical circulatory support (cardiopulmonary exercise testing);	I	C
– should be considered to optimize prescription of exercise training (preferably cardiopulmonary exercise testing);	IIa	C
– should be considered to identify the cause of unexplained dyspnoea (cardiopulmonary exercise testing);	IIa	C
– may be considered to detect reversible myocardial ischaemia.	IIa	C
Chest radiography (X-ray) is recommended in patients with HF to detect/exclude alternative pulmonary or other diseases, which may contribute to dyspnoea. It may also identify pulmonary congestion/oedema and is more useful in patients with suspected HF in the acute setting.	I	C

Diagnostic tests in patients with heart failure (3)

Recommendations	Class	Level
<p>Right heart catheterization with a pulmonary artery catheter:</p> <ul style="list-style-type: none"> – is recommended in patients with severe HF being evaluated for heart transplantation or mechanical circulatory support; – should be considered in patients with probable pulmonary hypertension assessed by echocardiography in order to confirm pulmonary hypertension and its reversibility before the correction of valve/structural heart disease; – may be considered in order to adjust therapy in patients with HF who remain severely symptomatic despite initial standard therapies and whose haemodynamic status is unclear. 	<p>I</p> <p>IIa</p> <p>IIb</p>	<p>C</p> <p>C</p> <p>C</p>
<p>EMB should be considered in patients with rapidly progressive HF despite standard therapy when there is a probability of a specific diagnosis which can be confirmed only in myocardial samples and specific therapy is available and effective.</p>	IIa	C
<p>Thoracic ultrasound may be considered for the confirmation of pulmonary congestion and pleural effusion in patients with AHF.</p>	IIb	C
<p>Ultrasound measurement of inferior vena cava diameter may be considered for the assessment of volume status in patients with HF.</p>	IIb	C

Prevent or delay the development of overt heart failure or prevent death before the onset of symptoms (1)

Recommendations	Class	Level
Treatment of hypertension is recommended to prevent or delay the onset of HF and prolong life.	I	A
Treatment with statins is recommended in patients with or at high-risk of CAD whether or not they have LV systolic dysfunction, in order to prevent or delay the onset of HF and prolong life.	I	A
Counselling and treatment for smoking cessation and alcohol intake reduction is recommended for people who smoke or who consume excess alcohol in order to prevent or delay the onset of HF.	I	C
Treating other risk factors of HF (e.g. obesity, dysglycaemia) should be considered in order to prevent or delay the onset of HF.	IIa	C
Empagliflozin should be considered in patients with type 2 diabetes in order to prevent or delay the onset of HF and prolong life.	IIa	B
ACE-I is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction in order to prevent or delay the onset of HF and prolong life.	I	A


Prevent or delay the development of overt heart failure or prevent death before the onset of symptoms (2)

Recommendations	Class	Level
ACE-I is recommended in patients with asymptomatic LV systolic dysfunction without a history of myocardial infarction, in order to prevent or delay the onset of HF.	I	B
ACE-I should be considered in patients with stable CAD even if they do not have LV systolic dysfunction, in order to prevent or delay the onset of HF.	IIa	A
Beta-blocker is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction, in order to prevent or delay the onset of HF or prolong life.	I	B
ICD is recommended in patients: a) with asymptomatic LV systolic dysfunction (LVEF $\leq 30\%$) of ischaemic origin, who are at least 40 days after acute myocardial infarction; b) with asymptomatic non-ischaemic dilated cardiomyopathy (LVEF $\leq 30\%$), who receive OMT therapy, in order to prevent sudden death and prolong life.	I	B

Pharmacological treatments in patients with symptomatic (NYHA Class II-IV) heart failure with reduced ejection fraction

Recommendations	Class	Level
An ACE-I is recommended, in addition to a beta-blocker, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death.	I	A
A beta-blocker is recommended, in addition an ACE-I, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death.	I	A
An MRA is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACE-I and a beta-blocker, to reduce the risk of HF hospitalization and death.	I	A

Therapeutic algorithm for a patient with symptomatic heart failure with reduced ejection fraction



Evidence-based doses of disease-modifying drugs in key randomized trials in HF with reduced ejection fraction (or after myocardial infarction)

	Starting dose (mg)	Target dose (mg)
ACE-I		
Captopril	6.25 <i>t.i.d.</i>	50 <i>t.i.d.</i>
Enalapril	2.5 <i>b.i.d.</i>	10–20 <i>b.i.d.</i>
Lisinopril	2.5–5.0 <i>o.d.</i>	20–35 <i>o.d.</i>
Ramipril	2.5 <i>o.d.</i>	10 <i>o.d.</i>
Trandolapril	0.5 <i>o.d.</i>	4 <i>o.d.</i>
Beta-blockers		
Bisoprolol	1.25 <i>o.d.</i>	10 <i>o.d.</i>
Carvedilol	3.125 <i>b.i.d.</i>	25 <i>b.i.d.</i>
Metoprolol succinate (CR/XL)	12.5–25 <i>o.d.</i>	200 <i>o.d.</i>
Nebivolol	1.25 <i>o.d.</i>	10 <i>o.d.</i>
ARBs		
Candesartan	4–8 <i>o.d.</i>	32 <i>o.d.</i>
Valsartan	40 <i>b.i.d.</i>	160 <i>b.i.d.</i>
Losartan	50 <i>o.d.</i>	150 <i>o.d.</i>
MRAs		
Eplerenone	25 <i>o.d.</i>	50 <i>o.d.</i>
Spironolactone	25 <i>o.d.</i>	50 <i>o.d.</i>
ARNI		
Sacubitril/valsartan	49/51 <i>b.i.d.</i>	97/103 <i>b.i.d.</i>
If -channel blocker		
Ivabradine	5 <i>b.i.d.</i>	7.5 <i>b.i.d.</i>

Doses of diuretics commonly used in patients with heart failure

Diuretics	Initial dose (mg)		Usual daily dose (mg)	
Loop diuretics				
Furosemide	20–40		40–240	
Bumetanide	2.5–1.0		1–5	
Torasemide	5–10		10–20	
Thiazides				
Bendroflumethiazide	2.5		2.5–10	
Hydrochlorothiazide	25		12.5–100	
Metolazone	2.5		2.5–10	
Indapamide	2.5		2.5–5	
Potassium-sparing diuretics				
	+ACE-1/ARB	-ACE-1/ARB	+ACE-1/ARB	-ACE-1/ARB
Spirolactone/eplerenone	12.5–25	50	50	100–200
Amiloride	2.5	5	5–10	10–20
Triamterene	25	50	100	200

Other pharmacological treatments recommended in selected patients with symptomatic (NYHA Class II-IV) HF with reduced ejection fraction (1)

Recommendations	Class	Level
Diuretics		
Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion.	I	B
Diuretics should be considered to reduce the risk of HF hospitalization in patients with signs and/or symptoms of congestion.	IIa	B
Angiotensin receptor neprilysin inhibitor		
Sacubitril/valsartan is recommended as a replacement for an ACE-I to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE-I, a beta-blocker and an MRA.	I	B
If-channel inhibitor		
Ivabradine should be considered to reduce the risk of HF hospitalization or cardiovascular death in symptomatic patients with LVEF $\leq 35\%$, in sinus rhythm and a resting heart rate ≥ 70 bpm despite treatment with an evidence-based dose of betablocker (or maximum tolerated dose below that), ACE-I (or ARB), and an MRA (or ARB).	IIa	B
Ivabradine should be considered to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients with LVEF $\leq 35\%$, in sinus rhythm and a resting heart rate ≥ 70 bpm who are unable to tolerate or have contra-indications for a beta-blocker. Patients should also receive an ACE-I (or ARB) and an MRA (or ARB).	IIa	C

Other pharmacological treatments recommended in selected patients with symptomatic (NYHA Class II-IV) HF with reduced ejection fraction (2)

Recommendations	Class	Level
ARB		
An ARB is recommended to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients unable to tolerate an ACE-I (patients should also receive a beta-blocker and an MRA).	I	B
An ARB may be considered to reduce the risk of HF hospitalization and death in patients who are symptomatic despite treatment with a beta-blocker who are unable to tolerate an MRA.	IIb	C
Hydralazine and isosorbide dinitrate		
Hydralazine and isosorbide dinitrate should be considered in self-identified black patients with LVEF $\leq 35\%$ or within LVEF $< 45\%$ combined with a dilated LV in NYHA Class III-IV despite treatment with an ACE-I a beta-blocker and an MRA to reduce the risk of HF hospitalization and death.	IIa	B
Hydralazine and isosorbide dinitrate may be considered in symptomatic patients with HFrEF who can tolerate neither an ACE-I nor an ARB (or they are contra-indicated) to reduce the risk of death.	IIb	B
Other treatments with less-certain benefits		
Digoxin		
Digoxin may be considered in symptomatic patients in sinus rhythm despite treatment with an ACE-I (or ARB), a beta-blocker and an MRA, to reduce the risk of hospitalization (both all-cause and HF-hospitalizations).	IIb	B
N-3 PUFA		
An n-3 PUFA preparation may be considered in symptomatic HF patients to reduce the risk of cardiovascular hospitalization and cardiovascular death.	IIb	B

Treatments (or combinations of treatments) that may cause harm in patients with symptomatic (NYHA Class II-IV) HF with reduced ejection fraction

Recommendations	Class	Level
Thiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization.	III	A
NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization.	III	B
Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF hospitalization.	III	C
The addition of an ARB (or renin inhibitor) to the combination of an ACE-I and an MRA is not recommended in patients with HF, because of the increased risk of renal dysfunction and hyperkalaemia.	III	C

Implantable cardioverter-defibrillator in patients with heart failure

Recommendations	Class	Level
<p>Secondary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status.</p>	I	A
<p>Primary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA Class II-III), and an LVEF $\leq 35\%$ despite ≥ 3 months of OMT, provided they are expected to survive substantially longer than one year with good functional status, and they have:</p> <ul style="list-style-type: none"> • IHD (unless they have had an MI in the prior 40 days – see below). • DCM. 	I	A
	I	B
ICD implantation is not recommended within 40 days of an MI as implantation at this time does not improve prognosis.	III	A
ICD therapy is not recommended in patients in NYHA Class IV with severe symptoms refractory to pharmacological therapy unless they are candidates for CRT, a ventricular assist device, or cardiac transplantation.	III	C
Patients should be carefully evaluated by an experienced cardiologist before generator replacement, because management goals and the patient's needs and clinical status may have changed.	IIa	B
A wearable ICD may be considered for patients with HF who are at risk of sudden cardiac death for a limited period or as a bridge to an implanted device.	IIb	C

Cardiac resynchronization therapy implantation in patients with heart failure (1)

Recommendations	Class	Level
CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration ≥ 150 msec and LBBB QRS morphology and with LVEF $\leq 35\%$ despite OMT in order to improve symptoms and reduce morbidity and mortality.	I	A
CRT should be considered for symptomatic patients with HF in sinus rhythm with a QRS duration ≥ 150 msec and non-LBBB QRS morphology and with LVEF $\leq 35\%$ despite OMT in order to improve symptoms and reduce morbidity and mortality.	IIa	B
CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration of 130–149 msec and LBBB QRS morphology and with LVEF $\leq 35\%$ despite OMT in order to improve symptoms and reduce morbidity and mortality.	I	B
CRT may be considered for symptomatic patients with HF in sinus rhythm with a QRS duration of 130–149 msec and non-LBBB QRS morphology and with LVEF $\leq 35\%$ despite OMT in order to improve symptoms and reduce morbidity and mortality.	IIb	B

Cardiac resynchronization therapy implantation in patients with heart failure (2)

Recommendations	Class	Level
CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA class who have an indication for ventricular pacing and high degree AV block in order to reduce morbidity. This includes patients with AF (see Section 10.1).	I	A
CRT should be considered for patients with LVEF $\leq 35\%$ in NYHA Class III–IVd despite OMT in order to improve symptoms and reduce morbidity and mortality, if they are in AF and have a QRS duration ≥ 130 msec provided a strategy to ensure bi-ventricular capture is in place or the patient is expected to return to sinus rhythm.	IIa	B
Patients with HFrEF who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite OMT and who have a high proportion of RV pacing may be considered for upgrade to CRT. This does not apply to patients with stable HF.	IIb	B
CRT is contra-indicated in patients with a QRS duration < 130 msec.	III	A

Treatment of patients with heart failure with preserved ejection fraction and heart failure with mid-range ejection fraction

Recommendations	Class	Level
it is recommended to screen patients with HFpEF or HFmrEF for both cardiovascular and noncardiovascular co-morbidities, which, if present, should be treated provided safe and effective interventions exist to improve symptoms, well-being and/or prognosis.	I	C
Diuretics are recommended in congested patients with HFpEF or HFmrEF in order to alleviate symptoms and signs.	I	B

Initial management of a rapid ventricular rate in patient with heart failure and atrial fibrillation in the acute or chronic setting

Recommendations	Class	Level
Urgent electrical cardioversion is recommended if AF is thought to be contributing to the patient's haemodynamic compromise in order to improve the patient clinical condition.	I	C
For patients in NYHA Class IV, in addition to treatment for AHF, an intravenous bolus of amiodarone or, in digoxin-naïve patients, an intravenous bolus of digoxin should be considered to reduce the ventricular rate.	IIa	B
For patients in NYHA Class I–III, a beta-blocker, usually given orally, is safe and therefore is recommended as first-line treatment to control ventricular rate, provided the patient is euvolaemic.	I	A
For patients in NYHA Class I–III, digoxin, should be considered when ventricular rate remains high despite beta-blockers or when beta-blockers are not tolerated or contra-indicated.	IIa	B
AV node catheter ablation may be considered to control heart rate and relieve symptoms in patients unresponsive or intolerant to intensive pharmacological rate and rhythm control therapy, accepting that these patients will become pacemaker dependent.	IIb	B
Treatment with dronedarone to improve ventricular rate control is not recommended due to safety concerns.	III	A

A rhythm control management strategy in patients with atrial fibrillation, symptomatic heart failure (NYHA II-IV) and left ventricular systolic dysfunction and no evidence of acute decompensation

Recommendations	Class	Level
Electrical cardioversion or pharmacological cardioversion with amiodarone may be considered in patients with persisting symptoms and/or signs of HF, despite OMT and adequate control of ventricular rate, to improve clinical/symptomatic status.	IIb	B
AF ablation may be considered in order to restore sinus rhythm to improve symptoms in patients with persisting symptoms and/or signs of HF, despite OMT and adequate control of ventricular rate, to improve clinical/symptomatic status.	IIb	B
Amiodarone may be considered prior to (and following) successful electrical cardioversion to maintain sinus rhythm.	IIb	B
Dronedarone is not recommended because of an increased risk of hospital admissions for cardiovascular causes and an increased risk of premature death in NYHA Class III-IV patients.	III	A
Class I antiarrhythmic agents are not recommended because of an increased risk of premature death.	III	A

The prevention of thrombo-embolism in patients with symptomatic heart failure (NYHA Class II-IV) and paroxysmal or persistent/permanent atrial fibrillation (1)

Recommendations	Class	Level
The CHA ₂ DS ₂ -VAS _c and HAS-BLED scores are recommended tools in patients with HF for the estimation of the risk of thromboembolism and the risk of bleeding associated with oral anticoagulation, respectively.	I	B
An oral anticoagulant is recommended to prevent thrombo-embolism for all patients with paroxysmal or persistent/permanent AF and a CHA ₂ DS ₂ -VAS _c score ≥ 2 , without contra-indications, and irrespective of whether a rate or rhythm management strategy is used (including after successful cardioversion).	I	A
NOAC treatment is contra-indicated in patients with mechanical valves or at least moderate mitral stenosis.	III	B
In patients with AF of ≥ 48 h duration, or when the duration of AF is unknown, an oral anticoagulant is recommended at a therapeutic dose for ≥ 3 weeks prior to electrical or pharmacological cardioversion.	I	B

Prevention of thrombo-embolism in patients with symptomatic heart failure (NYHA Class II-IV) and paroxysmal or persistent/permanent atrial fibrillation (2)

Recommendations	Class	Level
Intravenous heparin or LMWH and TOE guided strategy is recommended for patients who have not been treated with an anticoagulant dose for ≥ 3 weeks and require urgent electrical or pharmacological cardioversion for a life threatening arrhythmia.	I	C
Combination of an oral anticoagulant and an antiplatelet agent is not recommended in patients with chronic (> 12 months after an acute event) coronary or other arterial disease, because of a high-risk of serious bleeding. Single therapy with an oral anticoagulant is preferred after 12 months.	III	C
For patients with HF and non-valvular AF eligible for anticoagulation based on a CHA_2DS_2 - VAS_c score, NOACs rather than warfarin should be considered for anticoagulation as NOACs are associated with a lower risk of stroke, intracranial haemorrhage and mortality, which outweigh the increased risk of gastrointestinal haemorrhage.	IIa	B

The management of ventricular tachyarrhythmias in heart failure

Recommendations	Class	Level
Potential aggravating/precipitating factors (e.g. low serum potassium/magnesium, ongoing ischaemia) should be sought and corrected in patients with ventricular arrhythmias.	IIa	C
Treatment with beta-blocker, MRA and sacubitril/valsartan reduces the risk of sudden death and is recommended for patients with HFrEF and ventricular arrhythmias (as for other patients) (see Section 7).	I	A
Implantation of an ICD or CRT-D device is recommended for selected patients with HFrEF (see Section 8).	I	A
Several strategies should be considered to reduce recurrent symptomatic arrhythmias in patients with an ICD (or in those who are not eligible for ICD), including attention to risk factors and optimal pharmacological treatment of HF, amiodarone, catheter ablation and CRT.	IIa	C
Routine use of antiarrhythmic agents is not recommended in patients with HF and asymptomatic ventricular arrhythmias because of safety concerns (worsening HF, proarrhythmia, and death).	III	A

The management of bradyarrhythmias in heart failure

Recommendations	Class	Level
When pauses >3 seconds are identified on the ECG, or if the bradycardia is symptomatic and the resting ventricular rate is <50 bpm in sinus rhythm or <60 bpm in AF, it should be considered whether there is need for any rate limiting medications prescribed; for patients in sinus rhythm beta-blockers should be reduced in dose or withdrawn only as a last resort.	IIa	C
For patients with symptomatic, prolonged or frequent pauses despite adjustment of rate limiting medication, either beta-blocker withdrawal or pacing may be considered as the next step.	IIb	C
Pacing solely to permit initiation or titration of beta-blocker therapy in the absence of a conventional pacing indication is not recommended.	III	C
In patients with HFrEF who require pacing and who have high degree AV block, CRT rather than RV pacing is recommended.	I	A
In patients with HFrEF who require pacing who do not have high degree AV block, pacing modes that avoid inducing or exacerbating ventricular dyssynchrony should be considered.	IIa	C

Importance of co-morbidities in patients with heart failure

1. Interfere with the diagnostic process of HF (e.g. COPD as a potentially confounding cause of dyspnoea).
2. Aggravate HF symptoms and further impair quality of life.
3. Contribute to the burden of hospitalizations and mortality, as the main cause of readmissions at 1 and 3 months.
4. May affect the use of treatments for HF (e.g. renin-angiotensin system inhibitors contra-indicated in some patients with severe renal dysfunction or beta-blockers relatively contra-indicated in asthma).
5. Evidence base for HF treatment is more limited as co-morbidities were mostly an exclusion criterion in trials; efficacy and safety of interventions is therefore often lacking in the presence of co-morbidities.
6. Drugs used to treat co-morbidities may cause worsening HF (e.g. NSAIDs given for arthritis, some anti-cancer drugs).
7. Interaction between drugs used to treat HF and those used to treat co-morbidities, resulting in lower efficacy, poorer safety, and the occurrence of side effects (e.g. beta-blockers for HFrEF and beta-agonists for COPD and asthma).

The treatment of stable angina pectoris with symptomatic (NYHA Class II-IV) heart failure with reduced ejection fraction (1)

Recommendations	Class	Level
Step 1		
A beta-blocker (in an evidence-based dose or maximum tolerated) is recommended as the preferred first-line treatment to relieve angina because of the associated benefits of this treatment (reducing the risk of HF hospitalization and the risk of premature death).	I	A
Step 2: On top of beta-blocker or if a beta-blocker is not tolerated		
ivabradine should be considered as an anti-anginal drug in suitable HFrEF patients (sinus rhythm and HR ≥ 70 bpm) as per recommended HFrEF management.	IIa	B
Step 3: For additional angina symptom relief - except from any combination not recommended		
A short-acting oral or transcutaneous nitrate should be considered (effective anti-anginal treatment, safe in HF).	IIa	A
A long acting oral or transcutaneous nitrate should be considered (effective anti-anginal treatment, not extensively studied in HF).	IIa	B
Trimetazidine may be considered when angina persists despite treatment with a beta-blocker (or alternative) to relieve angina (effective anti-anginal treatment, safe in HF).	IIb	A
Amlodipine may be considered in patients unable to tolerate a beta-blocker to relieve angina (effective anti-anginal treatment, safe in HF).	IIb	B

The treatment of stable angina pectoris with symptomatic (NYHA Class II-IV) heart failure with reduced ejection fraction (2)

Recommendations	Class	Level
Step 3: For additional angina symptom relief - except from any combination not recommended (<i>cont'd</i>)		
Nicorandil may be considered in patients unable to tolerate a beta-blocker to relieve angina (effective anti-anginal treatment, but safety in HF uncertain).	IIb	C
Ranolazine may be considered in patients unable to tolerate a beta-blocker to relieve angina (effective anti-anginal treatment, but safety in HF uncertain).	IIb	C
Step 4: Myocardial revascularization		
Myocardial revascularization is recommended when angina persists despite treatment with anti-angina drugs.	I	A
Alternatives to myocardial revascularization: combination of ≥ 3 antianginal drugs (from those listed above) may be considered when angina persists despite treatment with beta-blocker, ivabradine and an extra anti-angina drug (excluding the combinations not recommended below).	IIb	C
The following are NOT recommended:		
(1) Combination of any of ivabradine, ranolazine, and nicorandil because of unknown safety.	III	C
(2) Combination of nicorandil and a nitrate (because of lack of additional efficacy).	III	C
Diltiazem and verapamil are not recommended because of their negative inotropic action and risk of worsening HF.	III	C

The treatment of hypertension in patients with symptomatic (NYHA- Class II-IV) heart failure reduced ejection fraction (1)

Recommendations	Class	Level
Step 1		
ACE-I (or ARB) a beta-blocker or an MRA (or a combination) is recommended to reduce blood pressure as first-, second- and third line-therapy, respectively, because of their associated benefits in HFrEF (reducing the risk of death and HF hospitalization). They are also safe in HFpEF.	I	A
Step 2		
A thiazide diuretic (or if the patient is being treated with a thiazide diuretic, switching to a loop diuretic) is recommended to reduce blood pressure when hypertension persists despite treatment with a combination of an ACE-I (or alternatively ARB but NOT together with an ACE-I), a beta-blocker and an MRA.	I	C
Step 3		
Amlodipine or hydralazine is recommended to reduce blood pressure when hypertension persists despite treatment with a combination of an ACE-I (or alternatively ARB but NOT together with an ACE-I), a beta-blocker, an MRA and a diuretic.	I	A

The treatment of hypertension in patients with symptomatic (NYHA- Class II-IV) heart failure reduced ejection fraction (2)

Recommendations	Class	Level
Step 3 (cont'd)		
Felodipine should be considered to reduce blood pressure when hypertension persists despite treatment with a combination of an ACE-I (or alternatively ARB but NOT together with an ACE-I), a beta-blocker, an MRA and a diuretic.	IIa	B
Moxonidine is not recommended to reduce blood pressure because of safety concerns in HFrEF patients (increased mortality).	III	B
Alpha-adrenoceptor antagonists are not recommended to reduce blood pressure because of safety concerns in HFrEF patients (neurohormonal activation, fluid retention, worsening HF).	III	A
Diltiazem and verapamil are not recommended to reduce blood pressure in patients with HFrEF because of their negative inotropic action and risk of worsening HF.	III	C

The treatment for other co-morbidities in patients with heart failure

Recommendations	Class	Level
Iron deficiency		
Intravenous FCM should be considered in symptomatic patients with HFrEF and iron deficiency (serum ferritin <100 µg/L, or ferritin between 100–299 µg/L and transferrin saturation <20%) in order to alleviate HF symptoms, and improve exercise capacity and quality of life.	IIa	A
Diabetes		
Metformin should be considered as a first-line treatment of glycaemic control in patients with diabetes and HF, unless contra-indicated.	IIa	C

Treatment not recommended of other co-morbidities in patients with heart failure

Recommendations	Class	Level
Sleep apnoea		
Adaptive servo-ventilation is not recommended in patients with HFrEF and a predominant central sleep apnoea because of an increased all-cause and cardiovascular mortality.	III	B
Diabetes		
Thiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization.	III	A
Arthritis		
NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization.	III	B

Treatment of valvular diseases in patients with heart failure

Recommendations	Class	Level
In symptomatic patients with reduced LVEF and 'low-flow, low-gradient' aortic stenosis (valve area $<1 \text{ cm}^2$, LVEF $<40\%$, mean pressure gradient $<40 \text{ mmHg}$), low-dose dobutamine stress echocardiography should be considered to identify those with severe aortic stenosis suitable for valve replacement.	IIa	C
TAVI is recommended in patients with severe aortic stenosis who are not suitable for surgery as assessed by a 'heart team' and have predicted post-TAVI survival >1 year.	I	B
TAVI should be considered in high-risk patients with severe aortic stenosis who may still be suitable for surgery, but in whom TAVI is favoured by a 'heart team' based on the individual risk profile and anatomic suitability.	IIa	A
In patients with severe aortic regurgitation, aortic valve repair or replacement is recommended in all symptomatic patients and in asymptomatic patients with resting LVEF $\leq 50\%$, who are otherwise fit for surgery.	I	C
Evidence-based medical therapy in patients with HFrEF is recommended in order to reduce functional mitral regurgitation.	I	C
Combined surgery of secondary mitral regurgitation and coronary artery bypass grafting should be considered in symptomatic patients with LV systolic dysfunction (LVEF $<30\%$), requiring coronary revascularization for angina recalcitrant to medical therapy.	IIa	C
Isolated surgery of non-ischaemic regurgitant mitral valve in patients with severe functional mitral regurgitation and severe LV systolic dysfunction (LVEF $<30\%$) may be considered in selected patients in order to avoid or postpone transplantation.	IIb	C

Factors triggering acute heart failure

Acute coronary syndrome.

Tachyarrhythmia (e.g. atrial fibrillation, ventricular tachycardia).

Excessive rise in blood pressure.

Infection (e.g. pneumonia, infective endocarditis, sepsis).

Non-adherence with salt/fluid intake or medications.

Bradyarrhythmia.

Toxic substances (alcohol, recreational drugs).

Drugs (e.g. NSAIDs, corticosteroids, negative inotropic substances, cardiotoxic chemotherapeutics).

Exacerbation of chronic obstructive pulmonary disease.

Pulmonary embolism.

Surgery and perioperative complications.


Increased sympathetic drive, stress-related cardiomyopathy.

Metabolic/hormonal derangements (e.g. thyroid dysfunction, diabetic ketosis, adrenal dysfunction, pregnancy and peripartum related abnormalities).

Cerebrovascular insult.

Acute mechanical cause: myocardial rupture complicating ACS (free wall rupture, ventricular septal defect, acute mitral regurgitation), chest trauma or cardiac intervention, acute native or prosthetic valve incompetence secondary to endocarditis, aortic dissection or thrombosis.

Clinical profiles of patients with acute heart failure based on the presence/absence of congestion and/or hypoperfusion



Definitions of the terms used in Section 12 on acute heart failure (1)

Term	Definition
Symptoms/signs of congestion (left-sided)	Orthopnoea, paroxysmal nocturnal dyspnoea, pulmonary rales (bilateral), peripheral oedema (bilateral).
Symptoms/signs of congestion (right-sided)	Jugular venous dilatation, peripheral oedema (bilateral), congested hepatomegaly, hepatojugular reflux, ascites symptoms of gut congestion.
Symptoms/signs of hypoperfusion	Clinical: cold sweated extremities, oliguria, mental confusion, dizziness, narrow pulse pressure. Laboratory measures: metabolic acidosis, elevated serum lactate, elevated serum creatinine. Hypoperfusion is not synonymous with hypotension, but often hypoperfusion is accompanied by hypotension.
Hypotension	Systolic BP <90 mmHg
Bradycardia	Heart rate <40 bpm
Tachycardia	Heart rate >120 bpm
Abnormal respiratory effort	Respiratory rate >25 breaths/min with use of accessory muscles for breathing, or respiratory rate <8 breaths/min despite dyspnoea.

Definitions of the terms used in Section 12 on acute heart failure (2)

Term	Definition
Low O ₂ saturation	O ₂ saturation (SaO ₂) <90% in pulse oximetry Normal SaO ₂ neither excludes hypoxaemia (low PaO ₂) nor tissue hypoxia.
Hypoxaemia	O ₂ partial pressure (PaO ₂) in arterial blood <80 mmHg (<10,67 kPa) (blood gas analysis).
Hypoxaemic respiratory failure (type I)	PaO ₂ <60 mmHg (<8 kPa)
Hypercapnia	CO ₂ partial pressure (PaCO ₂) in arterial blood >45 mmHg (>6 kPa) (blood gas analysis).
Hypercapnic respiratory failure (type II)	PaCO ₂ >50 mmHg (>6,65 kPa).
Acidosis	pH <7.35
Elevated blood lactate	>2 mmol/L
Oliguria	Urine output <0.5 mL/kg/h

Initial management of a patient with acute heart failure

47

Patient with suspected AHF

Urgent phase after first medical contact

1. Cardiogenic shock?

Yes

Circulatory support

- pharmacological
- mechanical

No

2. Respiratory failure?

Yes

Ventilatory support

- oxygen
- non-invasive positive pressure ventilation (CPAP, BIPAP)
- mechanical ventilation

No

Immediate stabilization and transfer to ICU/CCU

Immediate phase (initial 60-120 minutes)

Identification of acute aetiology:

- C** acute **C**oronary syndrome
- H** **H**ypertension emergency
- A** **A**rrhythmia
- M** acute **M**echanical cause
- P** **P**ulmonary embolism

Yes

Immediate initiation of specific treatment

Follow detailed recommendations in the specific ESC Guidelines

No

Diagnostic work-up to confirm AHF
Clinical evaluation to select optimal management

Causes of elevated concentrations of natriuretic peptides

Cardiac		Non-cardiac	
	Heart failure		Advanced age
	Acute coronary syndromes		Ischaemic stroke
	Pulmonary embolism		Subarachnoid haemorrhage
	Myocarditis		Renal dysfunction
	Left ventricular hypertrophy		Liver dysfunction (mainly liver cirrhosis with ascites)
	Hypertrophic or restrictive cardiomyopathy		Paraneoplastic syndrome
	Valvular heart disease		Chronic obstructive pulmonary disease
	Congenital heart disease		Severe infections (including pneumonia and sepsis)
	Atrial and ventricular tachyarrhythmias		Severe burns
	Heart contusion		Anaemia
	Cardioversion, ICD shock		Severe metabolic and hormone abnormalities (e.g. thyro-toxicosis, diabetic ketosis)
	Surgical procedures involving the heart		
	Pulmonary hypertension		


Regarding applied diagnostic measurements

Recommendations	Class	Level
Upon presentation a measurement of plasma natriuretic peptide level (BNP, NT-proBNP or MR-proANP) is recommended in all patients with acute dyspnoea and suspected AHF to help in the differentiation of AHF from non-cardiac causes of acute dyspnoea.	I	A
At admission in all patients presenting with suspected AHF, the following diagnostic tests are recommended:		
a. 12-lead ECG;	I	C
b. chest X-ray to assess signs of pulmonary congestion and detect other cardiac or non-cardiac diseases that may cause or contribute to the patient's symptoms;	I	C
c. the following laboratory assessments in the blood: cardiac troponins, BUN (or urea), creatinine, electrolytes (sodium, potassium), glucose, complete blood count, liver function tests and TSH.	I	C
Echocardiography is recommended immediately in haemodynamically unstable AHF patients and within 48 hours when cardiac structure and function are either not known or may have changed since previous studies.	I	C

The management of patients with acute heart failure: oxygen therapy and ventilatory

Recommendations	Class	Level
Monitoring of transcutaneous arterial oxygen saturation (SpO ₂) is recommended.	I	C
Measurement of blood pH and carbon dioxide tension (possibly including lactate) should be considered, especially in patients with acute pulmonary oedema or previous history of COPD using venous blood. In patients with cardiogenic shock arterial blood is preferable.	IIa	C
Oxygen therapy is recommended in patients with AHF and SpO ₂ <90% or PaO ₂ <60 mmHg (8.0 kPa) to correct hypoxaemia.	I	C
Non-invasive positive pressure ventilation (CPAP, BiPAP) should be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SpO ₂ <90%) and started as soon as possible in order to decrease respiratory distress and reduce the rate of mechanical endotracheal intubation. Non-invasive positive pressure ventilation can reduce blood pressure and should be used with caution in hypotensive patients. Blood pressure should be monitored regularly when this treatment is used.	IIa	B
Intubation is recommended, if respiratory failure, leading to hypoxaemia (PaO ₂ <60 mmHg (8.0 kPa)), hypercapnia (PaCO ₂ >50 mmHg (6.65 kPa)) and acidosis (pH <7.35), cannot be managed non-invasively.	I	C

Management of patients with acute heart failure based on clinical profile during an early phase



The management of patients with acute heart failure: *pharmacotherapy* (1)

Recommendations	Class	Level
Diuretics		
Intravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of fluid overload to improve symptoms. It is recommended to regularly monitor symptoms, urine output, renal function and electrolytes during use of i.v. diuretics.	I	C
In patients with new-onset AHF or those with chronic, decompensated HF not receiving oral diuretics the initial recommended dose should be 20–40 mg i.v. furosemide (or equivalent); for those on chronic diuretic therapy, initial i.v. dose should be at least equivalent to oral dose.	I	B
It is recommended to give diuretics either as intermittent boluses or as a continuous infusion, and the dose and duration should be adjusted according to patients' symptoms and clinical status.	I	B
Combination of loop diuretic with either thiazide-type diuretic or spironolactone may be considered in patients with resistant oedema or insufficient symptomatic response.	IIb	C

The management of patients with acute heart failure: *pharmacotherapy* (2)

Recommendations	Class	Level
Vasodilators		
i.v. vasodilators should be considered for symptomatic relief in AHF with SBP >90 mmHg (and without symptomatic hypotension). Symptoms and blood pressure should be monitored frequently during administration of i.v. vasodilators.	IIa	B
In patients with hypertensive AHF, i.v. vasodilators should be considered as initial therapy to improve symptoms and reduce congestion.	IIa	B
Inotropic agents – dobutamine, dopamine, levosimendan, phosphodiesterase III (PDE III) inhibitors		
Short-term, i.v. infusion of inotropic agents may be considered in patients with hypotension (SBP <90 mmHg) and/or signs/symptoms of hypoperfusion despite adequate filling status, to increase cardiac, increase blood pressure, improve peripheral perfusion and maintain end-organ function.	IIb	C
An intravenous infusion of levosimendan or a PDE III inhibitor may be considered to reverse the effect of beta-blockade if beta-blockade is thought to be contributing to hypotension with subsequent hypoperfusion.	IIb	C
Inotropic agents are not recommended unless the patient is symptomatically hypotensive or hypoperfused because of safety concern.	III	A

The management of patients with acute heart failure: *pharmacotherapy* (3)

Recommendations	Class	Level
Vasopressors		
A vasopressor (norepinephrine preferably) may be considered in patients who have cardiogenic shock, despite treatment with another inotrope, to increase blood pressure and vital organ perfusion.	IIb	B
It is recommended to monitor ECG and blood pressure when using inotropic agents and vasopressors, as they can cause arrhythmia, myocardial ischaemia, and in the case of levosimendan and PDE III inhibitors also hypotension	I	C
In such cases intra-arterial blood pressure measurement may be considered.	IIb	C
Thrombo-embolism prophylaxis		
Thrombo-embolism prophylaxis (e.g. with LMWH) is recommended in patients not already anticoagulated and with no contra-indication to anticoagulation, to reduce the risk of deep venous thrombosis and pulmonary embolism.	I	B
Other drugs		
For acute control of the ventricular rate in patients with atrial fibrillation:		
a. digoxin and/or beta-blockers should be considered as the first-line therapy;	IIa	C
b. amiodarone may be considered.	IIb	B
Opiates may be considered for cautious use to relieve dyspnoea and anxiety in patients with severe dyspnoea but nausea and hypopnea may occur.	IIb	B

Intravenous vasodilators used to treat acute heart failure

Vasodilator	Dosing	Main side effects	Other
Nitroglycerine	Start with 10–20 µg/min, increase up to 200 µg/min	Hypotension, headache	Tolerance on continuous use
Isosorbide dinitrate	Start with 1 mg/h, increase up to 10 mg/h	Hypotension, headache	Tolerance on continuous use
Nitroprusside	Start with 0.3 µg/kg/min and increase up to 5 µg/kg/min	Hypotension, isocyanate toxicity	Light sensitive
Nesiritide	Bolus 2 µg/kg + infusion 0.01 µg/kg/min	Hypotension	

Positive inotropes and/or vasopressors used to treat acute heart failure

Vasodilator	Bolus	Infusion rate
Dobutamine	No	2–20 $\mu\text{g}/\text{kg}/\text{min}$ (beta ⁺)
Dopamine	No	3–5 $\mu\text{g}/\text{kg}/\text{min}$; inotropic (beta ⁺)
		> 5 $\mu\text{g}/\text{kg}/\text{min}$: (beta ⁺), vasopressor (alpha ⁺)
Milrinone	25–75 $\mu\text{g}/\text{kg}$ over 10–20 min	0.375–0.75 $\mu\text{g}/\text{kg}/\text{min}$
Enoximone	0.5–1.0 mg/kg over 5–10 min	5–20 $\mu\text{g}/\text{kg}/\text{min}$
Levosimendan	12 $\mu\text{g}/\text{kg}$ over 10 min (optional)	0.1 $\mu\text{g}/\text{kg}/\text{min}$, which can be decreased to 0.05 or increased to 0.2 $\mu\text{g}/\text{kg}/\text{min}$
Norepinephrine	No	0.2–1.0 $\mu\text{g}/\text{kg}/\text{min}$
Epinephrine	Bolus: 1 mg can be given i.v. during resuscitation, repeated every 3–5 min	0.05–0.5 $\mu\text{g}/\text{kg}/\text{min}$

Regarding renal replacement therapy in patients with acute heart failure

Recommendations	Class	Level
Ultrafiltration may be considered for patients with refractory congestion, who failed to respond to diuretic-based strategies.	IIb	B
Renal replacement therapy should be considered in patients with refractory volume overload and acute kidney injury.	IIa	C

Regarding oral evidence-based disease-modifying therapies in patients with acute heart failure

Recommendations	Class	Level
In case of worsening of chronic HFrEF, every attempt should be made to continue evidence-based, disease-modifying therapies, in the absence of haemodynamic instability or contra-indications.	I	C
In the case of de novo HFrEF, every attempt should be made to initiate these therapies after haemodynamic stabilization.	I	C

Regarding management of patients with cardiogenic shock

Recommendations	Class	Level
In all patients with suspected cardiogenic shock, immediate ECG and echocardiography are recommended.	I	C
All patients with cardiogenic shock should be rapidly transferred to a tertiary care center which has a 24/7 service of cardiac catheterization, and a dedicated ICU/CCU with availability of short-term mechanical circulatory support.	I	C
In patients with cardiogenic shock complicating ACS an immediate coronary angiography is recommended (within 2 hours from hospital admission) with an intent to perform coronary revascularization.	I	C
Continuous ECG and blood pressure monitoring are recommended.	I	C
Invasive monitoring with an arterial line is recommended.	I	C
Fluid challenge (saline or Ringer's lactate, >200 ml/15-30 min is recommended as the first-line treatment if there is no sign of overt fluid overload.	I	C
Intravenous inotropic agents (dobutamine) may be considered to increase cardiac output.	IIb	C
Vasopressors (norepinephrine preferable over dopamine) may be considered if there is a need to maintain SBP in the presence of persistent hypoperfusion.	IIb	B
IABP is not routinely recommended in cardiogenic shock.	III	B
Short-term mechanical circulatory support may be considered in refractory cardiogenic shock depending on patient age, co-morbidities and neurological function.	IIb	C

regarding monitoring of clinical status of patients hospitalized due to acute heart failure

Recommendations	Class	Level
Standard non-invasive monitoring of heart rate, rhythm, respiratory rate, oxygen saturation and blood pressure is recommended.	I	C
It is recommended that patients should be weighed daily and have an accurate fluid balance chart completed.	I	C
It is recommended to evaluate signs and symptoms relevant to HF (e.g. dyspnoea, pulmonary rales, peripheral oedema, weight) daily to assess correction of fluid overload.	I	C
Frequent, often daily, measurement of renal function (blood urea, creatinine) and electrolytes (potassium, sodium) during i.v. therapy and when renin-angiotensin-aldosterone system antagonists are initiated is recommended.	I	C
Intra-arterial line should be considered in patients with hypotension and persistent symptoms despite treatment.	IIa	C
Pulmonary artery catheter may be considered in patients who, despite pharmacological treatment present refractory symptoms (particularly with hypotension and hypoperfusion).	IIb	C

Goals of treatment in acute heart failure

Immediate (ED/ICU/CCU)

Improve haemodynamics and organ perfusion.

Restore oxygenation.

Alleviate symptoms.

Limit cardiac and renal damage.

Prevent thrombo-embolism.

Minimize ICU length of stay.

Intermediate (in hospital)

Identify aetiology and relevant co-morbidities.

Titrate therapy to control symptoms and congestion and optimize blood pressure.

Initiate and up-titrate disease-modifying pharmacological therapy.

Consider device therapy in appropriate patients.

Pre-discharge and long-term management

Develop a careplan that provides:

- A schedule for up-titration and monitoring of pharmacological therapy;
- Need and timing for review for device therapy;
- Who will see the patient for follow-up and when.

Enrol in disease management programme, educate, and initiate appropriate lifestyle adjustments.

Prevent early readmission.

Improve symptoms, quality of life, and survival.

Terms describing various indications for mechanical circulatory support

Bridge to decision (BTD)/ Bridge to bridge (BTB)	Use of short-term MCS (e.g. ECLS or ECMO) in patients with cardiogenic shock until haemodynamics and end-organ perfusion are stabilized, contra-indications for long-term MCS are excluded (brain damage after resuscitation) and additional therapeutic options including long-term VAD therapy or heart transplant can be evaluated.
Bridge to candidacy (BTC)	Use of MCS (usually LVAD) to improve end-organ function in order to make an ineligible patient eligible for heart transplantation.
Bridge to transplantation (BTT)	Use of MCS (LVAD or BiVAD) to keep patient alive who is otherwise at high risk of death before transplantation until a donor organ becomes available.
Bridge to recovery (BTR)	Use of MCS (typically LVAD) to keep patient alive until cardiac function recovers sufficiently to remove MCS.
Destination therapy (DT)	Long-term use of MCS (LVAD) as an alternative to transplantation in patients with end-stage HF ineligible for transplantation or long-term waiting for heart transplantation.

INTERMACS* stage for classifying patients with advanced HF (1)

INTERMACS level	NYHA Class	Description	Device	1y survival with LVAD therapy
1. Cardiogenic shock "Crash and burn"	IV	Haemodynamic instability in spite of increasing doses of catecholamines and/or mechanical circulatory support with critical hypoperfusion of target organs (severe cardiogenic shock).	ECLS, ECMO, Percutaneous support devices	52.6±5.6%
2. Progressive decline despite inotropic support "Sliding on inotropes"	IV	Intravenous inotropic support with acceptable blood pressure but rapid deterioration of renal function, nutritional state, or signs of congestion.	ECLS, ECMO, LVAD	63.1±3.1%
3. Stable but inotrope dependent "Dependent stability"	IV	Haemodynamic stability with low or intermediate doses of inotropics, but necessary due to hypotension, worsening of symptoms, or progressive renal failure.	LVAD	78.4±2.5%

*Interagency Registry for Mechanically Assisted Circulatory Support

INTERMACS* stage for classifying patients with advanced HF (2)

INTERMACS level	NYHA Class	Description	Device	1y survival with LVAD therapy
4. Resting symptoms "Frequent flyer"	IV ambulatory	Temporary cessation of inotropic treatment is possible, but patient presents with frequent symptom recurrences and typically with fluid overload.	LVAD	78.7±3.0%
5. Exertion intolerant "Housebound"	IV ambulatory	Complete cessation of physical activity, stable at rest, but frequently with moderate fluid retention and some level of renal dysfunction.	LVAD	93.0±3.9%
6. Exertion limited "Walking wounded"	III	Minor limitation on physical activity and absence of congestion while at rest. Easily fatigued by light activity.	LVAD / Discuss LVAD as option	-
7. "Placeholder"	III	Patient in NYHA Class III with no current or recent unstable fluid balance.	Discuss LVAD as option	-

*Interagency Registry for Mechanically Assisted Circulatory Support

Patients potentially eligible for implantation of a left ventricular assist device

Patients with >2 months of severe symptoms despite optimal medical and device therapy and more than one of the following:

LVEF <25% and, if measured, peak VO_2 <12 mL/kg/min.

≥ 3 HF hospitalizations in previous 12 months without an obvious precipitating cause.

Dependence on i.v. inotropic therapy.

Progressive end-organ dysfunction (worsening renal and/or hepatic function) due to reduced perfusion and not to inadequate ventricular filling pressure (PCWP ≥ 20 mmHg and SBP ≤ 80 – 90 mmHg or CI ≤ 2 L/min/m²).

Absence of severe right ventricular dysfunction together with severe tricuspid regurgitation.

Implantation of mechanical circulatory support in patients with refractory heart failure

Recommendations	Class	Level
An LVAD should be considered in patients who have end-stage HFrEF despite optimal medical and device therapy and who are eligible for heart transplantation in order to improve symptoms, reduce the risk of HF hospitalization and the risk of premature death (Bridge to transplant indication).	IIa	C
An LVAD should be considered in patients who have end-stage HFrEF despite optimal medical and device therapy and who are not eligible for heart transplantation to, reduce the risk of premature death.	IIa	B

Heart transplantation: indications and contra-indications

Patients to consider	<p>End-stage HF with severe symptoms, a poor prognosis, and no remaining alternative treatment options.</p> <p>Motivated, well informed, and emotionally stable.</p> <p>Capable of complying with the intensive treatment required postoperatively.</p>
Contra-indications	<p>Active infection.</p> <p>Severe peripheral arterial or cerebrovascular disease.</p> <p>Pharmacologically irreversible pulmonary hypertension (LVAD should be considered with a subsequent reevaluation to establish candidacy).</p> <p>Cancer (a collaboration with oncology specialists should occur to stratify each patient as to their risk of tumour recurrence).</p> <p>Irreversible renal dysfunction (e.g. creatinine clearance <30 mL/min).</p> <p>Systemic disease with multi-organ involvement.</p> <p>Other serious co-morbidity with poor prognosis.</p> <p>Pre-transplant BMI >35 kg/m² (weight loss is recommended to achieve a BMI <35 kg/m²).</p> <p>Current alcohol or drug abuse.</p> <p>Any patient for whom social supports are deemed insufficient to achieve compliant care in the outpatient setting.</p>

Characteristics and components of management programmes for patients with heart failure

Characteristics	Should employ a multidisciplinary approach (cardiologists, primary care physicians, nurses, pharmacists, physiotherapists, dieticians, social workers, surgeons, psychologists, etc.).
	Should target high-risk symptomatic patients.
	Should include competent and professionally educated staff.
Components	Optimized medical and device management.
	Adequate patient education, with special emphasis on adherence and self-care.
	Patient involvement in symptom monitoring and flexible diuretic use.
	Follow-up after discharge (regular clinic and/or home-based visits; possibly telephone support or remote monitoring).
	Increased access to healthcare (through in-person follow-up and by telephone contact; possibly through remote monitoring).
	Facilitated access to care during episodes of decompensation.
	Assessment of (and appropriate intervention in response to) an unexplained change in weight, nutritional status, functional status, quality of life, or laboratory findings.
	Access to advanced treatment options.
	Provision of psychosocial support to patients and family and/or caregivers.

Exercise, multidisciplinary management and monitoring of patients with heart failure

Recommendations	Class	Level
It is recommended that regular aerobic exercise is encouraged in patients with HF to improve functional capacity and symptoms.	I	A
It is recommended that regular aerobic exercise is encouraged in stable patients with HFrEF to reduce the risk of HF hospitalization.	I	A
It is recommended that patients with HF are enrolled in a multidisciplinary care management programme to reduce the risk of HF hospitalization and mortality.	I	A
Referral to primary care for longterm follow-up may be considered for stable HF patients who are on optimal therapy to monitor for effectiveness of treatment, disease progression and patient adherence.	IIb	B
Monitoring of pulmonary artery pressures using a wireless implantable haemodynamic monitoring system (CardioMems) may be considered in symptomatic patients with HF with previous HF hospitalization in order to reduce the risk of recurrent HF hospitalization.	IIb	B
Multiparameter monitoring based on ICD (IN-TIME approach) may be considered in symptomatic patients with HFrEF (LVEF $\leq 35\%$) in order to improve clinical outcomes.	IIb	B

Key topics and self-care skills to include in patient education and the professional behaviours to optimize learning and facilitate shared decision making (1)

Education topic	Patient skills	Professional behaviours
Definition, aetiology and trajectory of HF (including prognosis)	<ul style="list-style-type: none"> • Understand the cause of HF, symptoms and disease trajectory. • Make realistic decisions including decisions about treatment at end-of-life. 	<ul style="list-style-type: none"> • Provide oral and written information that takes account of educational grade and health literacy. • Recognize HF disease barriers to communication and provide information at regular time intervals. • Sensitively communicate information on prognosis at time of diagnosis, during decision making about treatment options, when there is a change in the clinical condition and whenever the patient requests.
Symptom monitoring and self-care	<ul style="list-style-type: none"> • Monitor and recognize change in signs and symptoms. • Know how and when to contact a healthcare professional. • In line with professional advice, know when to self-manage diuretic therapy and fluid intake. 	<ul style="list-style-type: none"> • Provide individualized information to support self-management such as: <ul style="list-style-type: none"> → In the case of increasing dyspnoea or oedema or a sudden unexpected weight gain of >2 kg in 3 days, patients may increase their diuretic dose and/or alert their healthcare team. → Use of flexible diuretic regime. → Self-care support aids such as dosette box when appropriate.
Pharmacological treatment	<ul style="list-style-type: none"> • Understand the indications, dosing and side effects of drugs. • Recognize the common side effects and know when to notify a healthcare professional. • Recognize the benefits of taking medication as prescribed. 	<ul style="list-style-type: none"> • Provide written and oral information on dosing, effects and side effects (see web tables 7.4-7.8 practical guidance on use of pharmacological agents).

Key topics and self-care skills to include in patient education and the professional behaviours to optimize learning and facilitate shared decision making (2)

Education topic	Patient skills	Professional behaviours
Implanted devices and percutaneous/surgical interventions	<ul style="list-style-type: none"> • Understand the indications and aims of procedures/implanted devices. • Recognize the common complications and know when to notify a healthcare professional. • Recognize the importance and benefits of procedures/ implanted devices. 	<ul style="list-style-type: none"> • Provide written and oral information on benefits and side effects. • Provide written and oral information on regular control of device functioning, along with documentation of regular check-up.
Immunization	<ul style="list-style-type: none"> • Receive immunization against influenza and pneumococcal disease. 	<ul style="list-style-type: none"> • Advise on local guidance and immunization practice.
Diet and alcohol	<ul style="list-style-type: none"> • Avoid excessive fluid intake. • Recognize need for altered fluid intake such as: <ul style="list-style-type: none"> → Increase intake during periods of high heat and humidity, nausea/vomiting → Fluid restriction of 1.5–2 L/day may be considered in patients with severe HF to relieve symptoms and congestion. • Monitor body weight and prevent malnutrition. • Eat healthily, avoid excessive salt intake (>6 g/day) and maintain a healthy body weight. • Abstain from or avoid excessive alcohol intake, especially. 	<ul style="list-style-type: none"> • Individualize information on fluid intake to take into account body weight and periods of high heat and humidity. Adjust advice during periods of acute decompensation and consider altering these restrictions towards end-of-life. • Tailor alcohol advice to aetiology of HF; e.g. abstinence in alcoholic cardiomyopathy. • Normal alcohol guidelines apply (2 units per day in men or 1 unit per day in women). 1 unit is 10 mL of pure alcohol (e.g. 1 glass of wine, 1/2 pint of beer, 1 measure of spirit). • For management of obesity (see Section 11.15).

Key topics and self-care skills to include in patient education and the professional behaviours to optimize learning and facilitate shared decision making (3)

Education topic	Patient skills	Professional behaviours
Smoking and recreational substance use	<ul style="list-style-type: none"> • Stop smoking and taking recreational substances. 	<ul style="list-style-type: none"> • Refer for specialist advice for smoking cessation and drug withdrawal and replacement therapy. • Consider referral for cognitive behavioural theory and psychological support if patient wishes support to stop smoking.
Exercise	<ul style="list-style-type: none"> • Undertake regular exercise sufficient to provoke mild or moderate breathlessness. 	<ul style="list-style-type: none"> • Advice on exercise that recognizes physical and functional limitations, such as frailty, co-morbidities. • Referral to exercise programme when appropriate.
Travel and leisure	<ul style="list-style-type: none"> • Prepare travel and leisure activities according to physical capacity. • Monitor and adapt fluid intake according to humidity (driest and humid climates) • Be aware of adverse reactions to sun exposure with certain medication (such as amiodarone). • Consider effect of high altitude on oxygenation. • Take medicine in cabin luggage in the plane, have a list with you of treatments and the dosage with the generic name. 	<ul style="list-style-type: none"> • Refer to local country specific driving regulations regarding ICD. • Provide advice regarding flight security devices in presence of ICD.

Key topics and self-care skills to include in patient education and the professional behaviours to optimize learning and facilitate shared decision making (4)

Education topic	Patient skills	Professional behaviours
Sleep and Breathing (see co-morbidities Section 11.16)	<ul style="list-style-type: none"> • Recognize problems with sleeping, their relationship with HF and how to optimize sleep. 	<ul style="list-style-type: none"> • Provide advice such as timing of diuretics, environment for sleep, device support. • In presence of sleep-disordered breathing provide advice on weight reduction/control.
Sexual activity (see co-morbidities Section 11.7)	<ul style="list-style-type: none"> • Be reassured about engaging in sex, provided sexual activity does not provoke undue symptoms. • Recognize problems with sexual activity, their relationship with HF and applied treatment and how to treat erectile dysfunction. 	<ul style="list-style-type: none"> • Provide advice on eliminating factors predisposing to erectile dysfunction and available pharmacological treatment of erectile dysfunction. • Refer to specialist for sexual counselling when necessary.
Psychosocial Aspects	<ul style="list-style-type: none"> • Understand that depressive symptoms and cognitive dysfunction are found more frequently in people with HF, and that they may affect adherence. • Recognize psychological problems which may occur in the course of disease, in relation to changed lifestyle, pharmacotherapy, implanted devices and other procedures (including mechanical support and heart transplantation). 	<ul style="list-style-type: none"> • Regularly communicate information on disease, treatment options and self-management. • Involve family and carers in HF management and self-care. • Refer to specialist for psychological support when necessary.

Specific recommendations regarding monitoring and follow-up of the older adult with heart failure

Monitor frailty and seek and address reversible causes (cardiovascular and non-cardiovascular) of deterioration in frailty score.

Medication review: optimize doses of heart failure medication slowly and with frequent monitoring of clinical status. Reduce polypharmacy; number, doses and complexity of regime. Consider stopping medication without an immediate effect on symptom relief or quality of life (such as statin). Review the timing and dose of diuretic therapy to reduce risk of incontinence.

Consider need to refer to specialist care of the elderly team and to general practitioner and social worker, etc. for follow-up and support for the patient and his/her family.

Patients with heart failure in whom end of life care should be considered

Progressive functional decline (physical and mental) and dependence in most activities of daily living.

Severe heart failure symptoms with poor quality of life despite optimal pharmacological and non-pharmacological therapies.

Frequent admissions to hospital or other serious episodes of decompensation despite optimal treatment.

Heart transplantation and mechanical circulatory support ruled out.

Cardiac cachexia.

Clinically judged to be close to end of life.

Key components of palliative care service in patients with heart failure

Focus on improving or maintaining the quality of life of a patient and his/her family as well as possible until he/she dies.

Frequent assessment of symptoms (including dyspnoea and pain) resulting from advanced heart failure and other co-morbidities and focus on symptom relief.

Access for the patient and his/her family to psychological support and spiritual care according to need.

Advanced care planning, taking account of preferences for place of death and resuscitation (which may include deactivating devices, such as pacemaker and/or implantable cardioverter defibrillator).

To do and not to do messages from the Guidelines (1)

Recommendations	Class	Level
Cardiac imaging in patients with suspected or established heart failure		
TTE is recommended for the assessment of myocardial structure and function in subjects with suspected HF in order to establish a diagnosis of either HFrEF, HFmrEF or HFpEF.	I	C
TTE is recommended for the assessment of LVEF in order to identify patients with HF who would be suitable for evidence-based pharmacological and device (ICD, CRT) treatment recommended for HFrEF.	I	C
Aiming to prevent or delay the development of overt heart failure or prevent death before the onset of symptoms		
Treatment of hypertension is recommended to prevent or delay the onset of HF and prolong life.	I	A
ACE-I is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction in order to prevent or delay the onset of HF and prolong life.	I	A
Beta-blocker is recommended in patients with asymptomatic LV systolic dysfunction and a history of myocardial infarction, in order to prevent or delay the onset of HF and prolong life.	I	B

To do and not to do messages from the Guidelines (2)

Recommendations	Class	Level
Pharmacological treatments indicated in patients with symptomatic heart failure with reduced ejection fraction		
An ACE-I is recommended, in addition to a beta-blocker, for symptomatic patients with HFrEF to reduce the risk of HF hospitalization and death.	I	A
A beta-blocker is recommended, in addition to an ACE-I, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death.	I	A
An MRA is recommended for patients with HFrEF, who remain symptomatic despite treatment with an ACE-I and a beta-blocker, to reduce the risk of HF hospitalization and death.	I	A
Other pharmacological treatments recommended in selected patients with symptomatic heart failure with reduced ejection fraction		
Diuretics are recommended in order to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion.	I	B
Sacubitril/valsartan is recommended as a replacement for an ACE-I to further reduce the risk of HF hospitalization and death in ambulatory patients with HFrEF who remain symptomatic despite optimal treatment with an ACE-I, a beta-blocker and an MRA.	I	B

To do and not to do messages from the Guidelines (3)

Recommendations	Class	Level
Treatments (or combinations of treatments) that may cause harm in patients with symptomatic (New York Heart Association Class II–IV) heart failure with reduced ejection fraction		
Diltiazem or verapamil are not recommended in patients with HFrEF, as they increase the risk of HF worsening and HF hospitalization.	III	C
The addition of an ARB (or a renin inhibitor) to the combination of an ACE-I and an MRA is not recommended in patients with HF, because of the increased risk of renal dysfunction and hyperkalaemia.	III	C
Implantable cardioverter-defibrillator in patients with heart failure		
Secondary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who are expected to survive for > 1 year with good functional status.	I	A

To do and not to do messages from the Guidelines (4)

Recommendations	Class	Level
Implantable cardioverter-defibrillator in patients with heart failure (<i>cont'd</i>)		
Primary prevention An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA Class II–III), and an LVEF $\leq 35\%$ despite ≥ 3 months of OMT, provided they are expected to survive substantially longer than 1 year with good functional status, and they have: <ul style="list-style-type: none"> • IHD (unless they have had an MI in the prior 40 days) • DCM 	I	A
	I	B
ICD implantation is not recommended within 40 days of an MI as implantation at this time does not improve prognosis.	III	A
Cardiac resynchronization therapy implantation in patients with heart failure		
CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration ≥ 150 msec and LBBB QRS morphology and with LVEF $\leq 35\%$ despite OMT in order to improve symptoms and reduce morbidity and mortality.	I	A

To do and not to do messages from the Guidelines (5)

Recommendations	Class	Level
Cardiac resynchronization therapy implantation in patients with heart failure (cont'd)		
CRT is recommended for symptomatic patients with HF in sinus rhythm with a QRS duration of 130–149 msec and LBBB QRS morphology and with LVEF \leq 35% despite OMT in order to improve symptoms and reduce morbidity and mortality.	I	B
CRT rather than RV pacing is recommended for patients with HFrEF regardless of NYHA Class who have an indication for ventricular pacing and high degree AV block in order to reduce morbidity. This includes patients with atrial fibrillation (see Section 10.1).	I	A
CRT is contra-indicated in patients with a QRS duration <130 msec.	III	A
Not-recommended treatments of co-morbidities in patients with heart failure		
Adaptive servo-ventilation is not recommended in patients with HFrEF and a predominant central sleep apnoea because of an increased all-cause and cardiovascular mortality.	III	B
Thiazolidinediones (glitazones) are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization.	III	A
NSAIDs or COX-2 inhibitors are not recommended in patients with HF, as they increase the risk of HF worsening and HF hospitalization.	III	B

To do and not to do messages from the Guidelines (6)

Recommendations	Class	Level
Regarding diagnostic measurements in patients with suspected acute heart failure		
Upon presentation a measurement of plasma natriuretic peptide level (BNP, NT-proBNP or MR-proANP) is recommended in all patients with acute dyspnoea and suspected AHF to help in the differentiation of AHF from non-cardiac causes of acute dyspnoea.	I	A
The management of patients with acute heart failure – pharmacotherapy		
Intravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of fluid overload to improve symptoms. It is recommended to regularly monitor symptoms, urine output, renal function and electrolytes during use of i.v. diuretics.	I	C
In patients with new-onset AHF or those with chronic, decompensated HF not receiving oral diuretics the initial recommended dose should be 20–40 mg i.v. furosemide (or equivalent); for those on chronic diuretic therapy, initial i.v. dose should be at least equivalent to oral dose.	I	B
It is recommended to give diuretics either as intermittent boluses or a continuous infusion, and the dose and duration should be adjusted according to the patients' symptoms and clinical status.	I	B

To do and not to do messages from the Guidelines (7)

Recommendations	Class	Level
The management of patients with acute heart failure – pharmacotherapy (cont'd)		
Inotropic agents are not recommended unless the patient is symptomatically hypotensive or hypoperfused because of safety concern.	III	A
Regarding management of patients with cardiogenic shock		
In all patients with suspected cardiogenic shock, immediate ECG and echocardiography are recommended.	I	C
All patients with cardiogenic shock should be rapidly transferred to a tertiary care centre which has a 24/7 service of cardiac catheterization, and a dedicated ICU/CCU with availability of short-term mechanical circulatory support.	I	C
Regarding oral evidence-based disease-modifying therapies in patients with acute heart failure		
In case of worsening of chronic HFrEF, every attempt should be made to continue evidence-based, disease-modifying therapies, in the absence of haemodynamic instability or contra-indications.	I	C

To do and not to do messages from the Guidelines (7)

Recommendations	Class	Level
Exercise, multidisciplinary management, and monitoring of patients with heart failure		
It is recommended that regular aerobic exercise is encouraged in patients with HF to improve functional capacity and symptoms.	I	A
It is recommended that regular aerobic exercise is encouraged in stable patients with HFrEF to reduce the risk of HF hospitalization.	I	A
It is recommended that patients with HF are enrolled in a multidisciplinary care management programme to reduce the risk of HF hospitalization and mortality.	I	A